Status:
COMPLETED
Can Supplemental Leucine Offset Disuse-induced Muscle Atrophy?
Lead Sponsor:
University of Birmingham
Conditions:
Muscle Disuse Atrophy
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
Ageing is associated with a gradual decline in muscle mass that is detrimental to both physical function and metabolic health, increasing the risk of morbidity and mortality. The loss of protein muscl...
Detailed Description
It is well established that skeletal muscle mass progressively declines with healthy ageing, a phenomenon commonly termed sarcopenia. Overtime, this leads to a loss in functional independence and prov...
Eligibility Criteria
Inclusion
- Age: 18-35 years old
- Sex: male
- BMI: 18-25 kg/m2
- Diagnosis and general health: Good general health defined as (i) no known cardiovascular or metabolic disease, ii) non-smokers, iii) accustomed to normal levels of physical activity
- Compliance: understands and is willing, able and likely to comply with all study procedures and restrictions.
- Consent: demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent
Exclusion
- Health problems such as: i) heart disease, ii) rheumatoid arthritis, iii) diabetes, iv) poor lung function, v) uncontrolled hypertension, vi) lactose intolerance or viI) any health conditions that might put the participant at risk for this study.
- Family history of thrombosis
- Involvement in regular structured exercise (resistance or endurance) training at the time of the study.
- Regular consumption of any analgesic or anti-inflammatory drug(s), either prescription or non-prescription
- Taking any medications known to affect protein metabolism (e.g. b-blockers, corticosteroids, non-steroidal anti- inflammatories, or prescription strength acne medications). Additional medications and/or supplementation aids (e.g. whey protein) will be deemed inappropriate based on the PI's discretion.
- Daily protein intake; individuals with protein intake that equates to \<0.8 or \>1.2 g/kg/day will be excluded from the proposed study, as altering the daily protein intake of individuals drastically over the 7 day period is expected to significantly impact muscle protein metabolism independent of the supplementation and/or immobilisation protocol.
- Infused with a stable isotope within 3 years prior to study participation
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2019
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03762278
Start Date
March 1 2017
End Date
May 1 2019
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Birmingham, School of Sport, Exercise and Rehabilitation Sciences
Edgbaston, West Midlands, United Kingdom, B15 2TT